174 related articles for article (PubMed ID: 22086725)
1. An efficient high-throughput screening method for MYST family acetyltransferases, a new class of epigenetic drug targets.
Falk H; Connor T; Yang H; Loft KJ; Alcindor JL; Nikolakopoulos G; Surjadi RN; Bentley JD; Hattarki MK; Dolezal O; Murphy JM; Monahan BJ; Peat TS; Thomas T; Baell JB; Parisot JP; Street IP
J Biomol Screen; 2011 Dec; 16(10):1196-205. PubMed ID: 22086725
[TBL] [Abstract][Full Text] [Related]
2. Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis.
Katsumoto T; Yoshida N; Kitabayashi I
Cancer Sci; 2008 Aug; 99(8):1523-7. PubMed ID: 18754862
[TBL] [Abstract][Full Text] [Related]
3. Advances in label-free screening approaches for studying histone acetyltransferases.
Rye PT; Frick LE; Ozbal CC; Lamarr WA
J Biomol Screen; 2011 Dec; 16(10):1186-95. PubMed ID: 21908798
[TBL] [Abstract][Full Text] [Related]
4. Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview.
Eglen RM; Reisine T
J Biomol Screen; 2011 Dec; 16(10):1137-52. PubMed ID: 22002420
[TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates.
Furdas SD; Kannan S; Sippl W; Jung M
Arch Pharm (Weinheim); 2012 Jan; 345(1):7-21. PubMed ID: 22234972
[TBL] [Abstract][Full Text] [Related]
6. Efficient hit-finding approaches for histone methyltransferases: the key parameters.
Ahrens T; Bergner A; Sheppard D; Hafenbradl D
J Biomol Screen; 2012 Jan; 17(1):85-98. PubMed ID: 21990582
[TBL] [Abstract][Full Text] [Related]
7. MYST family histone acetyltransferases take center stage in stem cells and development.
Voss AK; Thomas T
Bioessays; 2009 Oct; 31(10):1050-61. PubMed ID: 19722182
[TBL] [Abstract][Full Text] [Related]
8. MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells.
Yang XJ; Ullah M
Oncogene; 2007 Aug; 26(37):5408-19. PubMed ID: 17694082
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Activity Assays for MYST Histone Acetyltransferases and Adaptation for High-Throughput Inhibitor Screening.
McCullough CE; Marmorstein R
Methods Enzymol; 2016; 573():139-60. PubMed ID: 27372752
[TBL] [Abstract][Full Text] [Related]
10. High-throughput screening for identification of small molecule inhibitors of histone acetyltransferases using scintillating microplates (FlashPlate).
Turlais F; Hardcastle A; Rowlands M; Newbatt Y; Bannister A; Kouzarides T; Workman P; Aherne GW
Anal Biochem; 2001 Nov; 298(1):62-8. PubMed ID: 11673896
[TBL] [Abstract][Full Text] [Related]
11. Perspectives on the discovery of small-molecule modulators for epigenetic processes.
Lu Q; Quinn AM; Patel MP; Semus SF; Graves AP; Bandyopadhyay D; Pope AJ; Thrall SH
J Biomol Screen; 2012 Jun; 17(5):555-71. PubMed ID: 22392809
[TBL] [Abstract][Full Text] [Related]
12. The monocytic leukemia zinc finger protein MOZ is a histone acetyltransferase.
Champagne N; Pelletier N; Yang XJ
Oncogene; 2001 Jan; 20(3):404-9. PubMed ID: 11313971
[TBL] [Abstract][Full Text] [Related]
13. Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
Swaminathan V; Reddy BA; Ruthrotha Selvi B; Sukanya MS; Kundu TK
Subcell Biochem; 2007; 41():397-428. PubMed ID: 17484138
[TBL] [Abstract][Full Text] [Related]
14. Histone acetyl transferases as emerging drug targets.
Dekker FJ; Haisma HJ
Drug Discov Today; 2009 Oct; 14(19-20):942-8. PubMed ID: 19577000
[TBL] [Abstract][Full Text] [Related]
15. A bioluminogenic HDAC activity assay: validation and screening.
Halley F; Reinshagen J; Ellinger B; Wolf M; Niles AL; Evans NJ; Kirkland TA; Wagner JM; Jung M; Gribbon P; Gul S
J Biomol Screen; 2011 Dec; 16(10):1227-35. PubMed ID: 21832257
[TBL] [Abstract][Full Text] [Related]
16. The role of MOZ/KAT6A in hematological malignancies and advances in MOZ/KAT6A inhibitors.
Su J; Wang X; Bai Y; Sun M; Yao Y; Duan Y
Pharmacol Res; 2021 Dec; 174():105930. PubMed ID: 34626770
[TBL] [Abstract][Full Text] [Related]
17. The MYST family of histone acetyltransferases and their intimate links to cancer.
Avvakumov N; Côté J
Oncogene; 2007 Aug; 26(37):5395-407. PubMed ID: 17694081
[TBL] [Abstract][Full Text] [Related]
18. Progress in the discovery of small-molecule inhibitors of bromodomain--histone interactions.
Chung CW; Witherington J
J Biomol Screen; 2011 Dec; 16(10):1170-85. PubMed ID: 21956175
[TBL] [Abstract][Full Text] [Related]
19. TR-FRET cellular assays for interrogating posttranslational modifications of histone H3.
Machleidt T; Robers MB; Hermanson SB; Dudek JM; Bi K
J Biomol Screen; 2011 Dec; 16(10):1236-46. PubMed ID: 21972037
[TBL] [Abstract][Full Text] [Related]
20. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
Mai A; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
